Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Takes Over Radioligand Therapy Lutathera from Fujifilm in Japan
April 3, 2023
- Shionogi’s Xocova Now Available through Normal Commercial Channel
April 3, 2023
- Entyvio Hits Primary Goal in Pouchitis Study: Takeda
April 3, 2023
- Ultragenyx Plans Japan Submission of Evinacumab in May: CEO
March 31, 2023
- Takeda’s Iwasaki to Retire as Representative Director
March 31, 2023
- Pfizer Japan Files 20-Valent Pneumococcal Vaccine for Pediatric Use
March 31, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- JCR, Alexion Pair Up for Neurodegenerative Disease
March 31, 2023
- Twymeeg Tops GP Promotion Ranking 2 Months Running, Belsomra Most Detailed among HPs in February
March 31, 2023
- Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
- Astellas, Roche to Develop Combo Medical Device Solution for Diabetes
March 30, 2023
- Boehringer’s Japan Human Pharma Sales Up 5.6% in 2022
March 30, 2023
- Simulation Driven Decision-Making Support Necessary for R&D Strategy: Astellas Exec
March 29, 2023
- Pfizer Files Tick-Borne Encephalitis Vaccine in Japan
March 29, 2023
- Mochida, Human Life CORD Tie Up on Cell-Based Product in Japan
March 29, 2023
- Estimated 37,746 Patients Given Xocova as of March 19: Shionogi
March 29, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
- Janssen, Labor Union at Odds over Proposed Job Transfers: 2nd Bargaining Session
March 28, 2023
- Santen Files Epinastine Ophthalmic Cream for Allergic Conjunctivitis
March 28, 2023
- Teva Takeda to Copromote Allermist AG with Ceolia
March 28, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…